Product
DOR/3TC/TDF
Aliases
Delstrigo
2 clinical trials
9 indications
Indication
Body Weight ChangesIndication
HIVIndication
Antiretroviral TherapyIndication
Weight GainIndication
ObesityIndication
Minority healthIndication
BMDIndication
Metabolic SyndromeIndication
FastingClinical trial
Effect of Modified, Rapid-start, DOR/3TC/TDF or DOR + FTC/TAF or BIC/FTC/TAF on Body Weight and Composition, Metabolic Risk Parameters, and Measures of Bone Strength in Treatment-Naïve Black and Hispanic Women With HIV-1 InfectionStatus: Withdrawn, Estimated PCD: 2023-05-03
Clinical trial
Can the Weight Gain Associated With Use of Integrase Strand Inhibitors be Halted or Reversed With a Switch to Doravirine/Lamivudine/Tenofovir DF in Patients Living With HIV? (DeLiTE)Status: Terminated, Estimated PCD: 2024-03-31